Cipla (CIPLA) Stock Price, Fundamentals & Analysis

What CIPLA does

Cipla (CIPLA) is a stock listed on the National Stock Exchange of India in the Healthcare sector, specifically the Drug Manufacturers – Specialty & Generic industry. The company manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. Its portfolio includes generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations covering areas such as cardiovascular disease, respiratory conditions, HIV/AIDS, oncology, diabetes, and child health. Cipla also operates in consumer healthcare, biosimilars, and specialty businesses. It is incorporated in 1935 and headquartered in Mumbai, India, with 31,369 employees.

Key numbers explained

• The current price is 1,399.7 INR, up +0.05% today.
• The trailing P/E ratio of 33.6 shows how much investors pay per rupee of the last 12 months' earnings; a higher figure can suggest higher growth expectations.
• The forward P/E ratio of 22 uses expected future earnings, offering a different view of valuation.
• The dividend yield of 0.93% indicates the annual dividend as a percentage of the current price; the ex-dividend date is Jun 5, 2026.
• 31% of earnings are paid out as dividends, reflecting the share of profit returned to shareholders.
• The beta of 0.08 suggests the stock has historically moved much less than the overall market.
• The 52-week range is 1,165.7 – 1,673 INR, with the price down -6% over the past year.
• Revenue for the trailing 12 months is 280.68B INR, growing 3.5% year over year, with a profit margin of 12% and operating margin of 12.5%.
• The debt-to-equity ratio of 1.8 (in %) shows the relative weight of debt compared to shareholders' equity.
• The price-to-book ratio of 3.28 compares the market price to the company's book value per share.

What to watch

Investors tracking Cipla often look at the broader Healthcare sector and peers such as Sun Pharma (SUNPHARMA), Apollo Hospitals (APOLLOHOSP), Dr. Reddy's Laboratories (DRREDDY), and Max Healthcare (MAXHEALTH). For those interested in global comparisons, companies like EssilorLuxottica (EL), Shionogi (4507), and EBOS Group (EBO) operate in adjacent healthcare and pharmaceutical spaces. General factors to watch include regulatory changes in drug manufacturing, pricing pressure in generic markets, foreign exchange movements, and the company's next earnings report on Oct 29, 2026.